Molecular Partners (MOLN) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Molecular Partners (MOLN) has outperformed Protara Therapeutics (TARA) over the past year, gaining 2.7% versus a loss of 47.7%. Over five years, TARA leads with a -62.1% price change compared with -80.8% for MOLN. Protara Therapeutics is the larger company by market cap ($156.6 million vs $145.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MOLN | TARA |
|---|---|---|
| Share price | $3.81 | $2.65 |
| Market cap | $145.94M | $156.60M |
| 1-day change | 0.00% | +2.32% |
| YTD return | -12.59% | -50.28% |
| 1-year return | +2.70% | -47.73% |
| 5-year return | -80.76% | -62.13% |
| EPS (TTM) | $-1.71 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.36 | $7.82 |
| 52-week low | $3.53 | $2.51 |
| Distance from 52-week high | -28.92% | -66.11% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +172.18% | +870.19% |
| Average volume | 1.18K | 804.10K |
| Shares outstanding | 38.31M | 59.10M |
| Employees | 134 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MOLN has outperformed TARA by 50.4 percentage points over the past year.
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
MOLN vs TARA FAQ
Which is bigger, Molecular Partners or Protara Therapeutics?
Protara Therapeutics (TARA) is larger, with a market capitalization of $156.60M compared with $145.94M for Molecular Partners (MOLN).
Which stock has performed better over the past year, MOLN or TARA?
MOLN returned +2.70% over the past 12 months, compared with -47.73% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are Molecular Partners and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.